ESTRO早期乳腺癌靶区共识指南在DBCG Skagen Trial 1中的验证
本研究基于DBCG Skagen Trial 1的前瞻性数据,评估ESTRO 2015年早期乳腺癌选择性放疗靶区勾画共识指南的验证情况。该试验纳入2963例患者,所有临床靶区(CTV)勾画均遵循ESTRO指南。中位随访5.2年,78例出现局部区域复发,其中74例(95%)位于ESTRO定义的CTV内,仅3例边缘遗漏,支持该指南的靶区定义无需修改。
要点
- DBCG Skagen Trial 1中所有CTV勾画均遵循ESTRO指南,支持前瞻性验证。
- 78例局部区域复发中74例(95%)位于ESTRO定义的CTV内。
- 仅3例边缘遗漏,无证据提示需修改ESTRO靶区范围。
核心结论
- DBCG Skagen Trial 1的局部区域复发几乎全部位于ESTRO定义的CTV内,前瞻性验证了该指南,无证据提示需修改靶区。
研究设计与样本
- DBCG Skagen Trial 1纳入2963例患者(意向治疗队列2908例),所有CTV勾画遵循ESTRO 2015年早期乳腺癌选择性放疗靶区共识指南。
- 从影像和医疗记录中识别局部区域复发,并按与ESTRO定义CTV的关系分类为CTV内、边缘遗漏或远处复发。
主要发现
- 中位随访5.2年(IQR 4.1-6.7),78例患者发生局部区域复发,其中41例为孤立局部区域复发,37例伴同时性远处复发。
- 78例局部区域复发中74例(95%)位于ESTRO定义的CTV内,并计划接受全处方剂量。
- 所有局部复发均位于CTVp内,除3例患者外区域复发均位于CTVn内;仅识别出3例边缘遗漏。
关键数值与推荐
- ESTRO 2015年发布的早期乳腺癌选择性放疗靶区勾画共识指南用于本试验所有CTV勾画。
- 局部区域复发按与ESTRO定义CTV的关系分类:CTV内、边缘遗漏或远处复发。
临床怎么用
- 遵循ESTRO共识指南勾画早期乳腺癌CTV可有效覆盖局部区域复发高危区域。
- 本验证结果支持在临床实践中继续使用ESTRO指南进行靶区勾画,无需常规修改靶区范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Adjuvant loco-regional radiotherapy reduces recurrence risk and enhances survival in early-stage breast cancer. The ESTRO consensus guideline on target volume delineation for elective radiotherapy of early-stage breast cancer, published in 2015, sought to standardise contouring practices. In the DBCG Skagen Trial 1, all clinical target volume (CTV) delineations followed the ESTRO guideline, allowing pre-planned prospective validation. This study aimed to characterise the loco-regional recurrence (LRR) pattern in accordance with target delineation as per the ESTRO guideline. MATERIALS AND METHODS: DBCG Skagen Trial 1 enrolled 2,963 patients (2,908 in the intention-to-treat cohort). LRR, with or without concurrent distant recurrence, were identified from imaging and medical records, and categorised as inside the CTV, marginal miss, or distant recurrence relative to the ESTRO-defined CTVs. RESULTS: At median follow-up of 5.2 years (IQR 4.1-6.7), 78 patients developed LRR: 41 isolated LRR and 37 with concurrent distant recurrence. Among the 78 patients with LRR, 74 (95%) had recurrences located within the ESTRO-defined CTVs and were planned to receive the full prescribed dose. All local recurrences were within the CTVp, and all but three patients had regional recurrences within the CTVn. Only three marginal misses were identified. CONCLUSION: LRR in the DBCG Skagen Trial 1 occurred almost exclusively within the ESTRO-defined CTVs, providing prospective validation of the guideline, without evidence suggesting a need for modification of target volumes.
引用
- Høgsbjerg KW, Thomsen MS, Maae E, et al. Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1. Radiother Oncol. 2026. PMID: 42134665. doi:10.1016/j.radonc.2026.111594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。